

Management of Chronic Liver Failure

DEIRDRE KELLY

ESPGHAN GOES TO AFRICA

CAPETOWN

October 2013

End Stage Liver Failure

Aetiology of Chronic Liver Disease

- Neonatal liver disease
- Chronic hepatitis
- Metabolic
- Fibropolycystic liver disease
- Drugs

Neonatal Cholestasis

Extrahepatic:- Biliary atresia

Neonatal Hepatitis Syndrome (NHS)

- Intrauterine infection
- Inborn error of metabolism
- Biliary hypoplasia (Alagille/PFIC)
- Inborn errors of bile salt metabolism
- Prematurity
- Endocrine

TPN cholestasis

Chronic Liver Disease

- Chronic viral hepatitis (B&C)
- Autoimmune hepatitis
 - Type I (ANA, SMA +ve)
 - Type II (LKM +ve)
 - Sclerosing cholangitis
- Metabolic liver disease
 - Alpha-1-antitrypsin deficiency
 - Cystic fibrosis
 - Wilson's disease
- Non Alcoholic Fatty Liver Disease
- Drugs

Chronic Liver Disease

Jaundice may be absent

Malnutrition

Stunting

Hypersplenism


Low Hb, white cells and platelets

Bruising/petechiae/epistaxis

Hepatosplenomegaly



Multi-organ involvement in Liver Disease



Viral Hepatitis B & C

- World wide disease
- Perinatal transmission
- Chronic Asymptomatic Infection
- Acute Infection
 - Rare in childhood
- Significant risk of chronic liver disease
- Hepatocellular Carcinoma

Wilson's Disease

- Autosomal recessive:
- Incidence of 1:30,000 live births.
- The gene is on chromosome 13
- Encodes a copper transporting P-type ATPase-ATP7B ATPase.

Wilson's Disease

- Hepatic presentation < 12 years
 - Acute or chronic hepatitis/Failure
 - Haemolysis
 - Low alkaline phosphatase
- Neurological > 12 years
 - Slurred speech/Tremor /poor co-ordination
- Kayser Fleischer rings



Tyrosinaemia Type I

Incidence 1:50,000

Deficiency of fumaryl-aceto-acetase


Δ Succinyl acetone in urine

Deficiency of FAA in fibroblasts

Clinical Presentation of TTI

Chronic Liver Failure

- Failure to thrive
- Hepatosplenomegaly
- Rickets
- Cardiomyopathy
- Renal failure
- Neurological symptoms



Fatty Liver Disease

Definitions:

Non Alcoholic Fatty Liver Disease (NAFLD)

- hepatic steatosis without inflammation

Non Alcoholic Steatohepatitis (NASH)

- hepatic steatosis with hepatocellular injury
+/- fibrosis/cirrhosis

Fatty Liver Disease

Increasingly common cause of

- elevated transaminases
- hepatomegaly
- “bright” liver on ultra sound

Associated with Insulin Resistance

Diabetes type 2

Alstrom Syndrome

Bardet – Biedl Syndrome

Polycystic Ovary

Turner Syndrome

Lipodystrophy

Clinical features of Fatty Liver Disease

- Children more likely to be symptomatic
 - RUQ pain
 - Fatigue/malaise
- Most present coincidentally
 - Hepatomegaly
 - \uparrow ALT/AST (1.5 – 5 times normal)
 - ALT/AST ratio > 1 in most NAFLD
 - elevated triglycerides
 - acanthosis nigricans
 - insulin resistance



Treatment for Fatty Liver Disease

- **WEIGHT LOSS**
 - Diet and Exercise
 - cannabinoid receptor blockade (Rimonabant/Acomplia)
 - Lipase inhibition Orlistat
- **ANTIDIABETIC THERAPY – *Insulin sensitizer***
 - Glitazone
 - Metformin
- **ANTIOXIDATIVE THERAPY**
 - Vitamin E
- **ANTI LIPID THERAPY**
 - Statin
- **URSODEOXYCHOLIC ACID**

Hepatocellular Dysfunction in Children

Multi-organ failure

Primary:

Cardiac (Alagille, HOCM)

Renal (RTA)

Cerebral (mitochondrial disease)

Secondary:

Encephalopathy

Functional renal failure

Cardiac failure

Coagulopathy

Chronic Liver Disease in Children

Persistent liver disease (>8 weeks)

- Sustained hepatic dysfunction
- Biochemical/histological
- Functionally
 - Jaundice
 - Coagulopathy
 - Hypoglycaemia
 - Portal hypertension
 - Malnutrition

Effect of Hepatic Dysfunction

Cholestasis

- Pruritus
- Steatorrhoea
- Fat soluble vitamin deficiency
- Malnutrition



Management of End Stage Liver Failure

Supportive:


Prevention therapy:-

- Hepatic complications
- Sepsis

Nutritional support

Psychosocial

- child/family



Nutritional Management of End Stage Liver Failure

Modular feed: High protein/CHO
Balanced MCT/LCT

Low salt

150% RDA

Fat soluble vitamins A, D, E, K

- Oral
- Nasogastric
- Parenteral



Management of End Stage Liver Failure

Failure

Hepatic Encephalopathy

- Low protein diet (2g/kg)
- Lactulose 5.20 ml/day
- Neomycin 0.5 g TID
- Rifaxamine



Prompt treatment of sepsis/haemorrhage

Hepatocellular Dysfunction in Children

Fluid Management

Pathophysiology: Na/water retention

Ascites

Fluid overload

Management:

Fluid restriction

Calorie requirement

Management of End Stage Liver Failure Ascites and Fluid Retention

- Fluid and salt restriction
 - (2/3 maintenance)
- Diuretics: Spironolactone 3mg/kg
 Frusemide 1-2 mg/kg
- Ascitic tap/drainage
- Haemofiltration/Dialysis



Management of Pruritus

Enzyme inducers:-

- Phenobarbitone (5-15 mg/kg)
- Rifampicin (3 mg/kg)

Bile Diversion:-

- Ursodeoxycholic acid (20 mg/kg)
- Cholestyramine (1-4G/d)
- Biliary diversion

Central:-

- Naloxone
- Ondansetron

Management of End Stage Liver Failure

Coagulopathy:

Vitamin K 2-10 mgm/kg

Fresh frozen plasma 10 ml/kg

Cryoprecipitate

Platelets

Anaemia:

Oral iron

Transfusion

Management of End Stage Liver Failure

Specific:

Immunosuppression	(CAH)
Penicillamine	(Wilson's)
Ursodeoxycholic acid	(CF)
Anti-viral therapy	(Hep B/C)
Diet	
Liver Transplantation	

Hepatocellular Dysfunction in Children

Portal Hypertension:

- Varices
- Portal gastropathy
- Hypersplenism

Implications for a normal life:

- School
- Contact sports

Managing Portal Hypertension in Children

Medical Therapy

Diagnostic endoscopy and therapy

Drug therapy

**Transjugular intrahepatic porto-
systemic**

stent shunt (TIPSS)

Prophylaxis

Pharmacological Treatment of Portal Hypertension

Hepatic vascular resistance

Reduced by - nitric oxide
prostacyclin
adrenergic antagonists
calcium channel blocker

Portal blood flow


Reduced - vasopressin/lysypressin
Somatostatin/octreotide
propranolol

Prophylaxis of Portal Hypertension in Children

Drug therapy:


- Beta-blockers:
 - Propranolol, Nadolol
- 3 small studies in children
 - Bleeding in 15-33%
- No trials in children with CF
- ? Propranolol contraindicated in CF
- ? Losartan - angiotensin II receptor antagonist
- No trials of prophylactic band ligation in CF

Management of Acute Variceal Bleed in Childhood



Results of Variceal Band Ligation in Children

	N	Ablation	Rebleeding
Price	18	70%	30%
Fox	7	100%	28%
Karrer	7	100%	15%



Limitations of TIPPS Procedures in Children

Age/size of child

Size of portal vein (<2mm)


Size of stent (5-6 mm diameter)

Length of stent:- allow for growth

Long Term Outcome:

Encephalopathy

Occlusion/infection



Prognosis of Chronic Liver Disease

Depends on:-

- Aetiology
- Severity of insult
- Progression to cirrhosis
- Portal hypertension

Access to liver transplantation

Indications for Transplantation in Chronic Liver Failure

Laboratory Indices

Serum cholesterol <2.6 mmol/l (100 mg/dl)

Indirect bilirubin >100 $\mu\text{mol/l}$ (6mg/dl)

Serum albumin <35 g/l (3.5 mg/dl)

Prothrombin ration (INR) >1.4

Portal vein reverse flow on ultrasonography

Indications for Transplantation in Chronic Liver Failure

Clinical:-

Severe portal hypertension

Recurrent variceal bleeding

Refractory ascites


Intractable pruritus

Growth retardation

Unacceptable quality of life



Survival post transplant by disease (1989-2005)



Chronic Liver Disease

Chronic liver disease

Early referral and recognition of liver disease

Referral to Specialist centre

- Early diagnosis
- Consideration of Treatment
- Improve outcomes for children